Mosunetuzumab Plus Pola-CHP Compared with Pola-R-CHP in Previously Untreated DLBCL: Final Results from a Phase II Study.

Jason Westin, Tycel J. Phillips,Amitkumar Mehta, Marc S. Hoffmann, Eva Gonzalez-Barca,Catherine Thieblemont, Mariana Bastos-Oreiro, Richard Greil, Sebastian Giebel, Michael C. Wei, Jue Wang, Reinhard Bucher,Jason Sit,Elicia Penuel,Enkhtsetseg Purev, Donald L. Yee, Juan Miguel Bergua-Burgues

Blood Advances（2025）

Cited 0|Views1

Key words

diffuse large B-cell lymphoma,bispecific antibody,mosunetuzumab,T-cell engaging therapy,combination regimens

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined